Rezolute is a late-stage biopharmaceutical company developing treatments for rare metabolic diseases. The company's sole clinical asset is ersodetug, an intravenously administered monoclonal antibody designed to treat refractory hypoglycemia caused by hyperinsulinism. Rather than suppressing insulin secretion, ersodetug binds directly to the insulin receptor to block excess downstream insulin signaling, enabling potential utility across multiple forms of the disease. Rezolute is evaluating ersodetug in two Phase 3 programs: congenital hyperinsulinism, a severe pediatric genetic condition, and tumor hyperinsulinism, which is caused by insulin-secreting tumors. Rezolute is pre-commercial, generates no product revenue, and funds its operations and clinical R&D through capital raises. If approved, Rezolute plans to commercialize ersodetug as a recurring intravenous therapy sold to hospitals, academic medical centers, and physicians treating orphan disease populations. Rezolute holds an exclusive worldwide license to ersodetug covering its underlying patents.